Trends of Primary and Subsequent Cancers of the Gastrointestinal Tract in the Czech Population, 1976–2005Dítě P.a · Geryk E.b
Departments of aGastroenterology and bEconomy, University Hospital, Brno, Czech Republic
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
A total of 355,624 new gastrointestinal (GI) cancers were registered in 1976–2005 in the Czech Cancer Registry. Of these, there were 14,744 (4.1%) primary and 26,790 (7.5%) subsequent cases, of which all were GI multiple cancers (12.1% males and 11.1% females). The primary GI cancers were followed by 16,362 other neoplasms (60.7% males, 39.3% females); the subsequent GI cancers were preceded by 31,519 other neoplasms (55.8% males, 44.2% females). Double neoplasms were higher in females, and multiple cases were higher in males. The number of primary cases peaked in 1997, the number of subsequent cases increased until 2005. Almost half of the cases were registered in the age group of 50–69 years. The average interval between primary GI cancers and subsequent neoplasms was 6.1 years; the ratio of synchronous to metachronous cases was 1:3.6 in males and 1:5 in females. The most frequent synchronous cases in males were cancers of other GI, urinary, genital and respiratory tract; in females these were cancers of other GI, genital and urinary tract and the breast. The most frequent cancers preceding the next subsequent GI cancer included primary cancers of the skin, other GI, genital, urinary and respiratory tract for males, and those of the skin, genital and other GI tract and breast cancer for females. The 23,462 subsequent GI cancers reported as a 2nd cancer included early stages in 29.6% of males and 27.9% of females, advanced stages in 31.2% males and 31.3% females, and unknown stages in 39.3% males and 40.8% females. Of 3,562 primary neoplasms of advanced stages before subsequent GI cancers, 2,093 were cases at stage III (51.4% males, 48.6% females) and 1,469 cases were at stage IV (60.2% males, 39.8% females); the most frequent in males were primary cancers of other GI, respiratory and genital tract, and cancers of other GI, breast and genital cancers in females. Of 9,568 primary neoplasms before subsequent GI cancers at advantage stages, 3,325 cases were registered before stage III (53.9% males, 46.1% females) and 6,243 cases before stage IV (57.7% males, 42.3% females). The most frequent in males were primary cancers of skin, other GI, genital and urinary tract; for women, the most frequent were those of the skin, genital cancers, breast and other GI tract. Up to October 2007, 78.2% males died and 21.8% survived primary GI cancers; for women, 76.6% of died and 23.4% survived. Of the subsequent GI cancers, 86.7% males died and 13.3% survived; for women, 85.7% died and 14.3% survived.
© 2010 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.